Psyence Biomedical PBM
NASDAQ PBM
$4.84 +0.10 (+2.11%)
At close: Sep 9, 2026 · 4:00 PM EDT

Psyence Biomedical (PBM) Non Operating Interest Expenses (2023 - 2025)

Psyence Biomedical (PBM) posted Non Operating Interest Expenses of -$2753.0 for Q3 2025, down 174.1% on a QoQ basis from $3715.0 in Q3 2024, and down 174.1% year-over-year from $3715.0 in Q3 2024.

Analysis

Psyence Biomedical (PBM) Non Operating Interest Expenses (2023 - 2025) Analysis & Trends

Psyence Biomedical has reported Non Operating Interest Expenses for 3 years, with the latest figure at -$2753.0 in Q3 2025.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -1.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 82.05 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn -
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 20.27 Mn
10 Psyence Biomedical 2.51 Mn 2.51 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -2,753.00
Sep 30, 2024 3,715.00
Sep 30, 2023 -27,936.00